APA ציטוט

Noronha, V., Patil, V., Joshi, A., Chougule, A., Bhattacharjee, A., Kumar, R., . . . Prabhash, K. (2017). Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy. Ecancermedicalscience.

Citação norma Chicago

Noronha, Vanita, et al. "Impact of Exon 19 Versus Exon 21 EGFR-activating Mutation On Outcomes With Upfront Pemetrexed–carboplatin Chemotherapy." Ecancermedicalscience 2017.

ציטוט MLA

Noronha, Vanita, et al. "Impact of Exon 19 Versus Exon 21 EGFR-activating Mutation On Outcomes With Upfront Pemetrexed–carboplatin Chemotherapy." Ecancermedicalscience 2017.